ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2486

Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG a And/or Two BILAG B Scores?

Ewa Olech1 and Joan Merrill2, 1IQVIA, Rheumatology Consultants, PLLC, Las Vegas, NV, 2Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: ACR Convergence 2023

Keywords: clinical trial, Outcome measures, Response Criteria, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: Abstracts: SLE – Treatment II: Nonrenal

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: High placebo response rates have challenged interpretation of clinical trial results in SLE and may have contributed to failure of some effective treatments. One hypothesis to explain inflated placebo responses is that patients may not have sufficient disease activity at baseline. Most study designs require at entry a score of ≥6 on the SLE Disease Activity Index (SLEDAI). Some have attempted to enrich for more active disease by adding an additional inclusion criterion using BILAG: score of A (severe) in ≥1 organ system and/or B (moderate) in ≥2 organ systems (BILAG restricted studies). However, the impact of this requirement on enrollment and study outcomes, including placebo responses, has not previously been examined.

Methods: Data from all reported phase II & III SLE trials with ≥100 subjects enrolled, at least 24 weeks treatment duration, and SLE responder index (SRI) and/or BILAG-based combined lupus assessment (BICLA) results were analyzed. In studies that did not require BILAG 1A or 2B at entry (BILAG non-restricted studies), the proportion of patients who nevertheless had at least 1 BILAG A or 2B was examined. BILAG restricted trials were compared to non-restricted for meeting primary endpoints, SRI-4, BICLA, placebo responses, and recruitment rates.

Results: Of 40 trials that met the initial search criteria, 3 were excluded from the analysis for not allowing BILAG A at screening (2 trials) and for major changes in entry criteria during study (1 trial). Of the 37 remaining studies (21 phase II and 16 phase III), 18 were BILAG-restricted and 19 non-restricted. In non-restricted studies, the mean percent of patients with at least 1 BILAG A or 2B scores was 62.7%.

Fifteen of 37 trials (41%) met the primary endpoint, including 6 of 18 (33%) restricted and 9 of 19 (47%) non-restricted studies (Figure 1). Of 36 studies with available SRI-4 data, this endpoint was met by 16 (44%) overall, 6 (33%) of 18 restricted and 10 (56%) of 18 non-restricted studies. Nineteen studies measured BICLA, which was met by 5 (26%) overall, including 4 (29%) of 14 restricted and 1 (25%) of 4 non-restricted.

Mean SRI-4 and BICLA placebo responses in all the studies were 43% and 36%: 44.3% and 36% in restricted studies, 41.7% and 35.9% in non-restricted studies.

Mean and median recruitment rates for all studies combined were 0.23 and 0.17 patients/site/month (p/s/m). BILAG restricted trials enrolled significantly slower than non-restricted with mean/median 0.17/0.14 p/s/m versus 0.29/0.22 p/s/m (p=0.047, Mann-Whitney test, Figure 2).

Conclusion: Phase II and III SLE studies that require at least 1 BILAG A or 2B at screening are not more likely to meet their primary endpoint. BILAG-restriction does not decrease placebo responses. Furthermore, this entry criterion decreases the eligible patient pool by almost 40% significantly slowing recruitment rates.

Supporting image 1

Impact of at least 1 BILAG A or 2B inclusion criterion on study results: comparison between trials with and without this requirement in meeting the primary endpoint, SRI_4 and BICLA (p=NS).

Supporting image 2

Impact of at least 1 BILAG A or 2B inclusion criterion on recruitment rates: comparison of recruitment rates between trials with and without this requirement (p = 0.047; Mann Whitney test)


Disclosures: E. Olech: AbbVie/Abbott, 2, 6, IQVIA, 3, Pfizer, 6, UCB, 6; J. Merrill: AbbVie, 2, Alexion, 2, Alumis, 2, Amgen, 2, AstraZeneca, 2, 5, Aurinia, 2, Bristol Myers Squibb, 2, 5, EMD Serono, 2, Genentech, 2, Gilead, 2, GlaxoSmithKline, 2, 5, Lilly, 2, Merck, 2, Pfizer, 2, Provention, 2, Remegen, 2, Sanofi, 2, UCB Pharma, 2, Zenas, 2.

To cite this abstract in AMA style:

Olech E, Merrill J. Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG a And/or Two BILAG B Scores? [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/should-sle-patients-entering-clinical-trials-be-required-to-have-at-least-one-bilag-a-and-or-two-bilag-b-scores/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/should-sle-patients-entering-clinical-trials-be-required-to-have-at-least-one-bilag-a-and-or-two-bilag-b-scores/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology